Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
复制标题
DOI：
10.1006/gyno.2001.6179
复制
发表时间：
2001-05
影响因子：
4.7
通讯作者：
G. Bolis;G. Scarfone;A. Villa;F. Parazzini
中科院分区：
文献类型：
--
作者：
G. Bolis;G. Scarfone;A. Villa;F. Parazzini
